Novartis To Offer Stiff Competition To Amgen’s Neupogen

Novartis To Offer Stiff Competition To Amgen’s Neupogen

FDA approval of Novartis AG’s Biologics License Application for filgrastim paves the way for Novartis to offer a cheaper version of Amgen’s Neupogen in the US

By Hannah Ishmael on Jul 25, 2014 at 6:20 am EST

Novartis To Offer Stiff Competition To Amgen’s Neupogen

comments powered by Disqus